2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1122

Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1683

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1649

Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1809

Influence of Solar Radiation in Cutaneous Manifestations of Lupus: Data from the Gladel Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1189

Inpatient Trends for Adults with Scleroderma in the United States: A 20 Year Analysis

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1562

Interaction Between Antibodies to Paraoxonase 1 and PON1 rs662 Polymorphism: New Clues to Understand HDL Dysfunction and Oxidative Stress in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1639

Interchangeability of Innovator Rituximab and Its Biosimilar: Results from International Controlled Comparative 1-Year Study in Patients with Active Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1232

Interdisciplinary Osteoporosis Clinical Working Group and Fracture Liaison Service at Loma Linda University Medical Center (LLUMC): Laying the Groundwork

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1925

Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1215

Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1126

Interleukin-1 Is Not Involved in Synovial Inflammation and Cartilage Destruction in Collagenase-Induced Osteoarthritis

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1120

Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1284

International Multi-Observer Ultrasound Reliability Study of Age Related Vascularization and Ossification in Healthy Children: The Omeract Pediatric Ultrasound Task Force

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1458

Intraadrenal Dendritic Cells Inhibit Corticosterone Response during Collagen-Induced Arthritis – a Role for IL-1β and CXC Chemokines?

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1178

Is Subclinical Atherosclerosis Prevalent in a French Patient Cohort with Systemic Lupus Erythematosus?

Epidemiology and Public Health - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].